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The complete amino acid sequence of human T-cell leukemia virus (HTLV) structural protein p15 has been 
determined. The intact protein and peptides generated by enzymatic digestion and acid cleavage were 
purified by reversed-phase liquid chromatography and subjected to semi-automated Edman degradation. 
HTLV ~15 is a basic linear polypeptide composed of 85 amino acids with Mr 9458. The primary structure 
indicates that HTLV ~15 is homologous to the nucleic acid binding proteins of other type-C retroviruses 
and especially related to bovine leukemia virus ~12. 
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The isolation of human T-cell leukemia-lym- 
phoma virus (HTLV) was first reported in [l]. 
Subsequently it has been shown that HTLV is an 
exogenous human retrovirus, etiologically associa- 
ted with a subtype of adult T-cell leukemia [2], and 
a number of additional isolates of HTLV have 
been obtained [3,4]. Extensive biochemical and im- 
munological studies provided evidence that HTLV 
is a unique retrovirus dinstinct from all previously 
known isolates [2,5]. Amino acid sequence analysis 
of the major internal protein p24 [6] confirmed 
these findings and revealed for the first time a 
structural relationship between HTLV p24 and 
protein homologs in other retroviruses, especially 
bovine leukemia virus (BLV). The initial NH2- 
terminal analysis and the results of ongoing studies 
show an - 37% homology of the major core pro- 
The structure of HLTV-Ica ~15 was presented at the 1st 
Annual Meeting of the American Society for Virology, 
Ithaca, New York, August 2-5, 1982 
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teins indicating a distant but definitive evolu- 
tionary relationship between HTLV and BLV. Ac- 
cumulated sequence data indicate that the basic 
nucleic acid binding proteins (NBP) of retroviruses 
are among the most highly conserved structural 
proteins encoded by the gag gene [7-g]. The amino 
acid sequence of BLV NBP (~12) has also been 
determined [lo]. We here report the determination 
of the complete amino acid sequence of the low - 
M, basic protein of HTLV, designated ~15. HTLV 
~15 contains the putative nucleic acid binding do- 
main involving a periodic placement of Cys 
residues [7-lo]. This and other primary structure 
data indicate that HTLV ~15 is a protein homolog 
of type C retrovirus NBPs. 
2. MATERIALS AND METHODS 
2.1. Krus 
Several isolates of HTLV are available now and 
can be grouped based on their biological and im- 
munological properties [3,4,11]. The strain desig- 
nated HTLV-1c~, grown in HUT-102 cells [1,3], 
was used here. 
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2.2. Protein and peptide purification 
The details of the purification of HTLV ~15 
from sucrose gradient-banded virus are described 
in [12]. Briefly, sucrose-purified HTLV was 
disrupted and subjected to ion exchange chromato- 
graphy on a phosphocellulose column. The peak 
eluting at 150-300 mM NaCl concentration con- 
taining mainly ~15 and p24 was used for further 
purification by reversed-phase liquid chromato- 
graphy (RPLC). The pH was lowered to pH 2 with 
aqueous trifluoroacetic acid (TFA). The sample 
was then applied to a Waters PBondapak Cl8 col- 
umn which was developed by a specially designed 
acetonitrile gradient in 0.05% TFA for 110 min, as 
shown in fig.1. The same column was used to 
separate peptide mixtures. Mixtures were either 
directly applied to the column after the pH had 
been adjusted to - 2.0 with aqueous TFA or small 
amounts of 6 M guanidine hydrochloride were 
added to the sample before the pH was adjusted 
and then applied to the column. Peptides were 
eluted with a 0.05% TFA-acetonitrile (CHsCH) 
gradient controlled by a Waters Model 660 solvent 
programmer and detected with a Waters 450 
variable wavelength detector. Peak fractions were 
collected manually and aliquots taken for amino 
acid analysis. 
2.3. Amino acid analysis 
The composition of HTLV ~15 and derived pep- 
tides were determined by amino acid analysis [ 131 
on a Durrum 500 amino acid analyzer. Samples 
Fig. 1. Reversed-phase liquid chromatography (RPLC) 
elution profile of HTLV ~15 and ~24. 
were hydrolyzed in vacua with 6 N HCl containing 
0.1% phenol at 110°C for 24 h. 
2.4. Liquid-phase sequencing 
Semi-automated Edman degradation [ 141 was 
performed on a Beckman sequenator updated to 
the level of a Model 890C [15], in the presence of 
Polybrene [ 161. A Waters PBondapak phenylalkyl 
column was used to identify and quantitate the 
phenylthiohydantoin (PTH) derivatives of amino 
acids [ 171. Samples were loaded onto the column 
with a Waters WISP 910A automated injector. 
2.5. Carboxyl- terminal analysis 
HTLV ~15 was digested with carboxypeptidase 
Y [ 181. Amino acids released were determined by 
amino acid analysis. 
2.6. Reduction and S-carboxamidomethylation 
The procedure used for reductive alkylation of 
protein is based on the original method in [19]. 
HTLV ~15 was reduced with dithiothreitol and 9 
carboxamidomethylated with iodoacetamide as in 
[7]. To remove excess reagents and side products, 
the pH of the reaction mixture was lowered to - 2 
with aqueous trifluoroacetic acid and the mixture 
was loaded onto a Cl8 RPLC column and the 
modified protein was eluted with an acetonitrile 
gradient. 
2.7. Lys-C digestion 
S-carboxamidomethyl ~15 was dissolved in 0.5 
ml 0.1 M NaHCO3 (pH 8.0) containing 20% 
acetonitrile [20]. Lys-C enzyme was added to give 
an enzyme/protein ratio of 1: 100. The reaction 
proceeded for 24 h at room temperature. Digestion 
was stopped by addition of aqueous TFA. 
2.8. Limited trypsin digestion 
The lysines of S-carboxamidomethyl ~15 were 
blocked with methylacetamide as in [7], the 
modified protein was dissolved in 0.1 M sodium 
bicarbonate (pH 8) with 1 M guanidine hydro- 
chloride and digested with TPCK trypsin (en- 
zyme/protein= 1: 100) for 22 h. 
2.9. Formic acid cleavage 
S-carboxamidomethyl ~15 was dissolved in 1.0 
ml 70% formic acid [21], reacted at 37°C for 47 h, 
diluted with water and lyophilized. 
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3. RESULTS AND DISCUSSION 
RPLC-purified HTLV ~15 (fig. 1) was homoge- 
nous by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) migrating with 
an apparent A4, of 15 000, hence the designation 
p15. 
The complete amino acid squence of HTLV ~15 
together with the sequencing strategy used is 
shown in fig.2. The primary structure was deter- 
mined by semi-automated microsequence analysis 
utilizing NHz-terminal Edman degradation of in- 
tact protein and fragments generated by various 
enzymatic and chemical cleavages (see legend to 
fig.2). Amino acid analyses were done on a Dur- 
rum 500 analyzer equipped with a PDP 8/A com- 
puting integrator. Values for the intact protein 
were based on the average of 3 samples hydrolyzed 
for 24, 48 and 72 h, respectively. HTLV ~15 had 
the following composition (values calculated from- 
the sequence are in parentheses): Asp 7.8 (6), Asn 
(2), Thr 4.1 (4), Ser 2.0 (2), Glu 8.9 (5), Gln (4), 
Pro 20.3 (20), Gly 4.9 (5), Ala 2.1 (2), Val 2.4 (3), 
Met 0 (0), Ile 2.8 (3), Leu 6.0 (6), Tyr 0 (0), Phe 
10 20 30 40 50 60 70 60 
0.9 (l), His 3.2 (3), Lys 5.9 (6), Arg 5.1 (5), Cys 
(6), Trp (2). Cysteine and tryptophan were not 
determined on the analyzer. The values for the 
other amino acids in excellent agreement with 
those derived from the complete sequence (fig.2). 
As with the intact protein, the compositions of the 
peptides (see fig.2) were also in good agreement 
with the number of residues found in the se- 
quences. To determine the COOH-terminal se- 
quence, 0.5 nmol of HTLV ~15 was digested with 
carboxypeptidase Y [ 181 for 40 min. Subsequent 
analysis gave the following results for the released 
amino acids (nmol/nmol protein): Val 0.89, Glu 
0.21, Gly 0.19. The deduced COOH-terminal se- 
quence is then: -(Gly,Glu)-Val-OH. 
HTLV ~15 is a linear polypeptide consisting of 
85 amino acid residues with a calculated M, of 
9458, a value which is substantially smaller than 
that estimated by SDS-PAGE. While this discre- 
pancy between the actual molecular mass and elec- 
trophoretic mobility is not understood, it is a fin- 
ding similar to previous observations made with 
low A4, highly polar retroviral proteins [7-lo]. The 
structural data indicate that HTLV ~15 is a basic 
VVQPKKPPPNQPCFRCGKAGHWSRDCTQPRPPPGPCPLCQDPTHWKRDCPRLKPTIPEPEPEEDALLLDLPTDIPHPKNSIGGEV 
Intact ~15 
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T5 
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Fig. 2. The complete amino acid sequence of HTLV ~15 and strategy for its determination. The structure shown was 
determined by semi-automated Edman degradation of intact protein and fragments derived from it by digestion with 
trypsin (fragments designated with letter T), by acid cleavage (fragments designated with letters AC) and endoproteinase 
Lys-C (fragment designated Lys-c). The length (number o’f residues) of each peptide is indicated by horizontal bars or 
arrows. Five peptides (Tl-T5) corresponding to the entire ~15 molecule were purified from the limited (lysine residues 
were blocked) trypsin digest. Two peptides were obtained and purified after formic acid cleavage (Acl and Ac2). From 
the Lys-C digest of the unreduced protein only the carboxyl-terminal peptide was pursued. The intact protein and all 
peptides were analyzed for composition and sequenced. Those peptides required to prove the structure are shown with 
bars, The shaded area indicates the extent to which sequence could be accurately determined. The letters under the bars 
indicate residues (single letter code) which could not be unambiguously identified in the given peptide. The single letter 
code for amino acids is as follows: A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, 
glycine; H, histidine; I, isoleucine; K, lycine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, 
arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine. 
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protein. It has 12 carboxyl groups (6 aspartic acid, 
5 glutamic acid and 1 cu-carboxyl group) and 15 
basic groups (3 hystidine, 6 lysine, 5 arginine, and 
1 u-amino group). It has no methionine or tyrosi- 
ne. The most abundant amino acid is proline 
(23.5%). In general this high proline content is 
unusual for the NBPs of other retroviruses and is 
a property of HTLV shared only with BLV. In ad- 
dition there are 6 cysteine residues in the structure 
of HTLV ~15 as found for BLV p12 [lo]. 
The alignment of the complete amino acid se- 
quences of HTLV ~15 and BLV p12 is shown in 
fig.3. The two proteins share the common 
NHz-terminus valine (position number 1). In the 
first 69 positions of the alignment where number- 
ing is based on the complete continuous sequence 
of BLV ~12, there are 36 identities (52.5%), 20 dif- 
ferences and 3 gaps (deletions) involving a total of 
13 positions (residues) shown by asterisks in the 
HTLV ~15 sequence. The extent of nucleotide se- 
5 10 1' 
PLY plZ ~-H~s-Thr-Pro-(;ly-~-~-Mct-Pro-Gly-Pro-A~q-~l~-F~n-Ala. 
iHTL" n15 )J&Val-61". f - __ _ _ L * -Pro-Lys-Lys-Fro-Fro-Pro-Asn-Cln- l l - 
2n 25 30 
NV pl7 Pro-Lys-Arq-Fro-Frn-Prn-~ly-~-~-Tyr-~-~-Le~,-~-fI,,- 
HTLV p15 l l * _ l l 1 _ l -Pro-Cys-Phe-Arrl-Cys-Gly-Lys-dla- 
35 4n 45 
RLV (112 ~ly-H~s-Tr~-Ala-Arq-Asp-Cys-Pro-Thr-Lys-Ala-Thr-6ly-Pro-Pro- -_- 
HTLV ~15 C,ly-His-Trp-Ser.Prq-~-~-lh~-~ln- * - * -Pro-Arq-Pro-Pro- -_ 
50 55 h" 
PLV p12 Pro-Gly-Fro-Cys-Pro-Ilr-~-Lys-~-~-S~~-~i~s-Tr~-tys-Ar~- ---- 
HTLV ~15 Pro-Cly-Frn-CyP-Pm-Le"-~-Gln-~-~-Thr-H,s-Trp-Lys-Arrl- 
HTLV ~15 Lys-Asn-car-Ile-T,ly-Gly-(;lu-Val 
Fig. 3. Sequence alignment of BLV p12 and HTLV ~15. 
Residues which are positionally identical are underlined. 
Asterisks idicate gaps introduced in the HTLV ~15 se- 
quence in order to maximize homology. Sequence of 
BLV p12 is taken from [lo]. 
quence identity between the genes coding for 
HTLV ~15 and BLV p12 remains to be seen. 
Because of the degeneracy in the genetic code, it 
could be less than the 52.5% identity at the amino 
level. It should be noted however that in the 20 
positions that are different, most of the substitu- 
tions could be the result of a single base change in 
the respective codon. In any event there are several 
identical amino acid sequence regions long enough 
to raise the possibility for the presence of identical 
nucleotide stretches detectable by nucleic acid 
hybridization. Nucleotide sequence homology has 
recently been found between molecularly cloned 
proviruses of HTLV and BLV using non-stringent 
molecular hybridization conditions (E. Gelman, R. 
Gallo, V. Manzari and F. Wong-Staal, in prepar- 
ation). 
The polypeptide chain of HTLV ~15 is 16 
residues longer than that of BLV ~12. The unique 
carboxyl-terminal sequence of HTLV beginning 
with position 70 of the alignment involves a total 
of 29 residues. This, together with the extent of 
amino acid sequence differences between HTLV 
~15 and BLV p12 in the comparable region (first 
69 residues), emphasizes the distinctness of the two 
viruses and the uniqueness of HTLV. 
Statistical analysis of the sequence data was car- 
ried out by the ALIGN program in [22]. This pro- 
gram is based on the mutation data matrix for 
scoring amino acid comparisons as published [22] 
and is designed to compute a numerical value for 
any given alignment of two sequences. When a 
break is introduced in order to obtain the best 
alignment, a penalty is assigned. Usually 300 ran- 
dom runs are performed to obtain the alignment 
score which is the number of standard deviations 
by which the maximum score for the real sequences 
exceeds the average maximum score for the ran- 
dom permutations. The alignment score calculated 
for BLV p12 and HTLV ~15 was 7.5 (table l), a 
highly significant value which indicates a definitive 
evolutionary relationship between HTLV and 
BLV. Alignments of the BLV p12 and HTLV ~15 
sequences with known sequences of NBPs of 
several type C viruses were also made. The align- 
ment scores obtained are summarized in table 1, It 
is seen that HTLV ~15 and BLV p12 are more 
related to each other than to NBPs of other 
retroviruses. An alignment score of 3.0 has been 
accepted as evidence implying common ancestry 
393 
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Table 1 
October 1983 
Alignment scoresa for the basic nucleic acid binding proteins of various type C virusesb 
BLVp12 R-MuLV,,o FeLV,lo ASVp12 
HTLV,H 7.5 4.4 3.8 4.0 
BLVp12 4.1 2.4 2.8 
R-MuLV,n, 13.0 4.6 
FeLV,lo 3.7 
“Number of standard deviations of real score above random score 
bSequences other than that of HTLV ~15 were taken from previous publications: BLV 
pl2 from [lo]; R-MuLV p10 from [7]; FeLV pl0 from [8] and ASV pl2 from [24] 
[22,23]. In this respect it is important to point out 
that the alignment of HTLV ~15 with the NBPs of 
Rauscher-murine leukemia virus (R-MuLV), feline 
leukemia virus (FeLV) and avian sarcoma virus 
(ASV) resulted in scores of 4.4, 3.8 and 4.0, respec- 
tively (table 1). BLV pl2 v.s R-MuLV pl0 scored a 
value of 4.1. The scores calculated for BLV pl2 
and FeLV p10 as well as for the BLV pl2 and ASV 
pl2 pair (2.4 and 2.8, respectively) are slightly 
below the value considered statistically significant 
(3.0 standard deviation above the mean) but FeLV 
~10 and ASV p12 show a significant relationship, 
not only to each other but to both R-MuLV ~10 
and HTLV ~15. The combined results of these 
statistical analyses therefore permit us to group 
HTLV ~15 and BLV ~12 together with the NBPs 
of the other type C viruses (both mammalian and 
avian) in an evolutionarily related superfamily of 
proteins. 
It has been previously shown that the putative 
nucleic acid binding domain including a set of 3 
cysteines is duplicated in BLV ~12 and ASV p12 
[lo]. Similar internal sequence homology also oc- 
curs in HTLV ~15. The alignment of these homo- 
logous regions is shown in fig.4. It is seen that in 
these 19-residue long segments a total of 10 amino 
acids are positionally identical. These again in- 
clude the 3 cysteines periodically placed at posi- 
tions n (first cysteine in each set), n + 3 and n + 13. 
HTLU ~15 
HTLU pi5 
Fig. 4. Internal duplication of sequence in HTLV ~15. In 
the alignment of the fragments the repeated residues are 
boxed. 
No internal sequence homology has been found in 
NBPs of the murine and feline type C viruses 
[7-lo]. Therefore, on the*basis of the occurrence 
of this partial sequence repetition due to gene 
duplication, HTLV ~15, BLV p12 and ASV pl2 
may be classified as forming a distinct family 
within the superfamily of type C virus NBPs as 
proposed above. 
The complete amino acid sequence of HTLV-1c~ 
~15 will allow characterization of additional new 
members of the HTLV family [3,4], including the 
adult T cell leukemia virus (ATLV) recently 
isolated in Japan [25], which is already known to 
be highly related to HTLV-Icn [4,1 I] and therefore 
a member of the HTLV group. During the prepa- 
ration of this manuscript, the complete nucleotide 
sequence of the proviral ATLV DNA was reported 
[26]. A comparison of the amino acid sequence of 
HTLV-ICR ~15 with the deduced sequence of 
ATLV shows a single amino acid difference only. 
Residue Thr” in HTLV-Icn ~15 is exchanged for 
Ala in ATLV. This may reflect a strain difference 
between the two independently isolated HTLVs. 
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